LABTRACE.ORG BETA LIVE
215 source polls this hour 65 244 articles collected last article 3m ago 1163 events on 2+ sources 0 embeddings/h feed queue 0 lag 352.5s
← health
LT-032902 / first seen 2026-10-19 17:02 / last activity 6h ago

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

measurement

heat
44 / 100 (raw 1.2)
velocity
0.0 independent sources per hour
solidity
97 / 100
sources
1 total, 1 independent
domain span
1 domain covered it

primary source

title
Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial
venue
The Lancet
status
peer-reviewed
doi
10.1016/s0140-6736(26)00967-0
published
2026-06-01

media coverage / 1 outlets